SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 70.12 |
| Enterprise Value ($M) | 65.64 |
| Book Value ($M) | -26.27 |
| Book Value / Share | -0.65 |
| Price / Book | -2.67 |
| NCAV ($M) | -32.25 |
| NCAV / Share | -0.80 |
| Price / NCAV | -2.17 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.82 |
| Current Ratio | 1.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 14.92 |
| Assets | 20.90 |
| Liabilities | 47.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Decheng Capital Management III (Cayman), LLC | 12.30 | 0.00 | |
| 13G/A | Ever Regal Group Ltd | 26.17 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,205 | 18,637 | 22.56 | |
| 5,050 | 20,000 | 25.25 | |
| 4,582 | 15,749 | 29.09 | |
| 5,465 | 19,800 | 27.60 | |
| 4,413 | 11,411 | 38.67 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BON – Bon Natural Life Limited | BPTH – Bio-Path Holdings, Inc. |
| BTAI – BioXcel Therapeutics, Inc. | CALC – CalciMedica, Inc. |
| CAPR – Capricor Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io